Compare Amgen, Inc. (AMGN) vs American States Water Company (AWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs American States Water Company — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while American States Water Company trades at $84.99 (market cap $3.31B). The key difference: Amgen, Inc. is far larger — about 59.3× American States Water Company's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | AWR | |
|---|---|---|
Market Cap | $196.12B | $3.31B |
Sector | Health | Utilities |
52-Week High | $388.16 | $84.76 |
52-Week Low | $271.18 | $70.10 |
Enterprise Value | $241.41B | $4.22B |
Dividend Yield | 2.77% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
American States Water (AWR) trades at $84.51, up 0.78% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported solid 2025 results with $658M revenue and $130M net income, maintaining a robust 19.66% net margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200M equity offering, reinforcing its stable utility model and 71-year dividend growth streak.
AWR offers defensive appeal with reliable dividends and infrastructure investments, but faces execution risks from regulatory approvals and interest rate sensitivity. Analyst consensus is mixed with 20% buy ratings, reflecting cautious optimism amid recent earnings misses. The stock's premium valuation (P/E 24.64) requires sustained growth to justify upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →
